Envestnet Asset Management Inc. Buys 62,757 Shares of Quanterix Co. (NASDAQ:QTRX)

Envestnet Asset Management Inc. increased its position in Quanterix Co. (NASDAQ:QTRX - Free Report) by 22.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 342,264 shares of the company's stock after acquiring an additional 62,757 shares during the quarter. Envestnet Asset Management Inc. owned about 0.89% of Quanterix worth $3,638,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Resona Asset Management Co. Ltd. purchased a new position in shares of Quanterix during the 4th quarter valued at $55,000. KLP Kapitalforvaltning AS bought a new stake in Quanterix during the fourth quarter valued at $66,000. Peapack Gladstone Financial Corp purchased a new position in Quanterix during the third quarter worth about $131,000. Levin Capital Strategies L.P. bought a new position in Quanterix in the 4th quarter worth about $159,000. Finally, Tallon Kerry Patrick purchased a new stake in shares of Quanterix in the 4th quarter valued at about $169,000. Hedge funds and other institutional investors own 86.48% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently commented on QTRX shares. Scotiabank reissued an "outperform" rating on shares of Quanterix in a report on Tuesday, March 25th. Canaccord Genuity Group cut their price target on shares of Quanterix from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, March 18th.

Quanterix Trading Down 1.7 %

Shares of QTRX traded down $0.10 during midday trading on Monday, reaching $5.78. The stock had a trading volume of 548,324 shares, compared to its average volume of 546,556. The company has a market capitalization of $224.20 million, a price-to-earnings ratio of -5.45 and a beta of 1.35. The company's 50-day moving average is $6.54 and its 200 day moving average is $9.53. Quanterix Co. has a 12-month low of $4.67 and a 12-month high of $19.18.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.03). The firm had revenue of $35.16 million during the quarter, compared to analysts' expectations of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. Research analysts forecast that Quanterix Co. will post -0.98 EPS for the current fiscal year.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.